Outcomes of Vanzacaftor–Tezacaftor–Deutivacaftor in Children (6–11 Years) with Cystic Fibrosis
发布者：Unknown
·发布于: 2025-12-13
Discussion regarding the safety, tolerability, and efficacy outcomes of vanzacaftor–tezacaftor–deutivacaftor treatment in children aged 6–11 years with cystic fibrosis.